Edition:
India

Assertio Therapeutics Inc (ASRT.OQ)

ASRT.OQ on NASDAQ Stock Exchange Global Select Market

1.40USD
23 Aug 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$1.40
Open
$1.55
Day's High
$1.55
Day's Low
$1.38
Volume
339,691
Avg. Vol
266,632
52-wk High
$7.42
52-wk Low
$1.27

About

Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution),... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $369.12
Shares Outstanding(Mil.): 62.99
Dividend: --
Yield (%): --

Financials

  ASRT.OQ Industry Sector
P/E (TTM): -- 29.89 32.67
EPS (TTM): -1.79 -- --
ROI: -12.06 14.89 14.48
ROE: -43.53 16.01 15.78

Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

NEW YORK Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.

29 Mar 2019

UPDATE 5-Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

NEW YORK, March 29 Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.

29 Mar 2019

CORRECTED-Intellia CEO not involved in Starboard's Bristol-Myers board challenge

NEW YORK, Feb 28 Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday.

02 Mar 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates